Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic T cells are engineered to express a CAR targeting a membrane antigen. In Europe, tisagenlecleucel (Kymriah™) is approved for the treatment of refractory/relapsed acute lymphoblastic leu...

Full description

Saved in:

Bibliographic Details
Published in:	Haematologica (Roma) Vol. 105; no. 2; pp. 297 - 316
Main Authors:	Yakoub-Agha, Ibrahim, Chabannon, Christian, Bader, Peter, Basak, Grzegorz W., Bonig, Halvard, Ciceri, Fabio, Corbacioglu, Selim, Duarte, Rafael F., Einsele, Hermann, Hudecek, Michael, Kersten, Marie José, Köhl, Ulrike, Kuball, Jürgen, Mielke, Stephan, Mohty, Mohamad, Murray, John, Nagler, Arnon, Robinson, Stephen, Saccardi, Riccardo, Sanchez-Guijo, Fermin, Snowden, John A., Srour, Micha, Styczynski, Jan, Urbano-Ispizua, Alvaro, Hayden, Patrick J., Kröger, Nicolaus
Format:	Journal Article
Language:	English
Published:	Italy Ferrata Storti Foundation 2020
Subjects:	Antigens, CD19 Bone Marrow Cancer Cell- and Tissue-Based Therapy Child Europe Guideline Hematology Human health and pathology Humans Immunology Immunotherapy Immunotherapy, Adoptive Life Sciences Receptors, Antigen, T-Cell - genetics Receptors, Chimeric Antigen Young Adult Europe
ISSN:	0390-6078, 1592-8721, 1592-8721
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!